Actively Recruiting
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
Led by Maastricht Radiation Oncology · Updated on 2026-04-23
600
Participants Needed
3
Research Sites
302 weeks
Total Duration
On this page
Sponsors
M
Maastricht Radiation Oncology
Lead Sponsor
Z
Zuyderland Medical Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer. In the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.
CONDITIONS
Official Title
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Patients with prostate cancer
- Patients planned for HDR brachytherapy treatment for high-risk or recurrent prostate cancer or transperineal prostate biopsy with MRI-suspected metastatic prostate cancer with at least clinical stage T3-4.
You will not qualify if you...
- Patients younger than 18 years
- Patients of whom it is not possible to obtain left-over tissue as part of the normal clinical treatment procedure (e.g., if all tumor material is required for diagnosis, staging, or molecular diagnosis).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Zuyderland Medisch Centrum
Heerlen, Limburg, Netherlands, 6419 PC
Not Yet Recruiting
2
Academisch Ziekenhuis Maastricht
Maastricht, Limburg, Netherlands, 6229 ET
Not Yet Recruiting
3
Maastricht Radiation Oncology
Maastricht, Limburg, Netherlands, 6229 ET
Actively Recruiting
Research Team
I
Iris EWG Laven, PhD
CONTACT
C
Chantal Overhof, BEc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here